Ablynx NV - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Ablynx NV - Product Pipeline Review - 2016', provides an overview of the Ablynx NV's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Ablynx NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Ablynx NV - The report provides overview of Ablynx NV including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Ablynx NV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Ablynx NV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ablynx NV - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ablynx NV's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Ablynx NV Snapshot 6 Ablynx NV Overview 6 Key Information 6 Key Facts 6 Ablynx NV - Research and Development Overview 7 Key Therapeutic Areas 7 Ablynx NV - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 Ablynx NV - Pipeline Products Glance 16 Ablynx NV - Late Stage Pipeline Products 16 Phase III Products/Combination Treatment Modalities 16 Ablynx NV - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Ablynx NV - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Ablynx NV - Drug Profiles 21 caplacizumab 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ALX-0061 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ozoralizumab 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ALX-0171 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ALX-0141 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibodies for Immunology and Oncology 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibodies for Inflammation and Osteoarthritis 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibodies for Multiple Sclerosis 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Monoclonal Antibody for Undisclosed Indication 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody to Target c-Met for Multiple Myeloma 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 TLC-520 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibodies to Agonize GITR for Immunology and Oncology 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody 1 for Oncology 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Monoclonal Antibody 2 for Oncology 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Ablynx NV - Pipeline Analysis 39 Ablynx NV - Pipeline Products by Target 39 Ablynx NV - Pipeline Products by Route of Administration 40 Ablynx NV - Pipeline Products by Molecule Type 41 Ablynx NV - Pipeline Products by Mechanism of Action 42 Ablynx NV - Recent Pipeline Updates 43 Ablynx NV - Dormant Projects 51 Ablynx NV - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 BI-1034020 52 Ablynx NV - Company Statement 53 Ablynx NV - Locations And Subsidiaries 55 Head Office 55 Other Locations & Subsidiaries 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Ablynx NV, Key Information 6 Ablynx NV, Key Facts 6 Ablynx NV - Pipeline by Indication, 2016 8 Ablynx NV - Pipeline by Stage of Development, 2016 10 Ablynx NV - Monotherapy Products in Pipeline, 2016 11 Ablynx NV - Partnered Products in Pipeline, 2016 12 Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2016 13 Ablynx NV - Out-Licensed Products in Pipeline, 2016 14 Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2016 15 Ablynx NV - Phase III, 2016 16 Ablynx NV - Phase II, 2016 17 Ablynx NV - Phase I, 2016 18 Ablynx NV - Preclinical, 2016 19 Ablynx NV - Discovery, 2016 20 Ablynx NV - Pipeline by Target, 2016 39 Ablynx NV - Pipeline by Route of Administration, 2016 40 Ablynx NV - Pipeline by Molecule Type, 2016 41 Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42 Ablynx NV - Recent Pipeline Updates, 2016 43 Ablynx NV - Dormant Developmental Projects,2016 51 Ablynx NV - Discontinued Pipeline Products, 2016 52 Ablynx NV, Subsidiaries 55
List of Figures
Ablynx NV - Pipeline by Top 10 Indication, 2016 8 Ablynx NV - Pipeline by Stage of Development, 2016 10 Ablynx NV - Monotherapy Products in Pipeline, 2016 11 Ablynx NV - Partnered Products in Pipeline, 2016 12 Ablynx NV - Out-Licensed Products in Pipeline, 2016 14 Ablynx NV - Pipeline by Target, 2016 39 Ablynx NV - Pipeline by Route of Administration, 2016 40 Ablynx NV - Pipeline by Molecule Type, 2016 41 Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.